nach oben

European Journal of Drug Metabolism and Pharmacokinetics

Erschienen in:

01.01.2022 | Review Article

Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review

verfasst von: Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny, Ebtehal El-Demerdash

Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Flavonoids are phytochemicals that are well known for their beneficial pharmacological properties. Diosmin is a flavone glycoside derived from hesperidin, a flavanone abundantly found in citrus fruits. Daflon is an oral phlebotonic flavonoid combination containing diosmin and hesperidin (9:1) that is commonly used for the management of blood vessel disorders. After oral administration, diosmin is converted to diosmetin, which is subsequently absorbed and esterified into glucuronide conjugates that are excreted in the urine. Pharmacological effects of diosmin have been investigated in several in vitro and in vivo studies, and it was found to possess anti-inflammatory, antioxidant, antidiabetic, antihyperlipidemic, and antifibrotic effects in different disease models. Diosmin also demonstrated multiple desirable properties in several clinical studies. Moreover, toxicological studies showed that diosmin has a favorable safety profile. Accordingly, diosmin is a potential effective and safe treatment for many diseases. However, diosmin exhibits inhibitory effects on different metabolic enzymes. This encourages the investigation of its potential therapeutic effect and safety in different diseases in clinical trials, while taking potential interactions into consideration.

Graphic Abstract

Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Therap. 2002;96:67–202.CrossRef

Mahomoodally MF, Gurib-Fakim A, Subratty AH. Antimicrobial activities and phytochemical profiles of endemic medicinal plants of Mauritius. Pharm Biol. 2005;43(3):237–42.CrossRef

Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. Sci World J. 2013.

Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. 1996;20:933–56.PubMedCrossRef

Campanero MA, Escolar M, Perez G, Garcia-Quetglas E, Sadaba B, Azanza JR. Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2010;51(4):875–81.PubMedCrossRef

Russo R, Chandradhara D, De Tommasi N. Comparative bioavailability of two diosmin formulations after oral administration to healthy volunteers. Molecules. 2018;23(9):2174.PubMedCentralCrossRef

Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63:71–100.PubMedCrossRef

Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF): Recommendations from the Working Group in Chronic Venous Disease (CVD) 2016. Phlebology. 2017;32(1_suppl):3–19.PubMedCrossRef

Maksimović ZV, Maksimović M, Jadranin D, Kuzmanović I, Andonović O. Medicamentous treatment of chronic venous insufficiency using semisynthetic diosmin–a prospective study. Acta Chir Iugosl. 2008;55(4):53–9.PubMedCrossRef

10.

Shelygin Y, Krivokapic Z, Frolov SA, Kostarev IV, Astashov VL, Vasiliev SV, et al. Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. Curr Med Res Opin. 2016;32(11):1821–6.PubMedCrossRef

11.

Jain D, Bansal MK, Dalvi R, Upganlawar A, Somani R. Protective effect of diosmin against diabetic neuropathy in experimental rats. J Integr Med. 2014;12(1):35–41.PubMedCrossRef

12.

Ahmed S, Mundhe N, Borgohain M, Chowdhury L, Kwatra M, Bolshette N, et al. Diosmin modulates the NF-kB signal transduction pathways and downregulation of various oxidative stress markers in alloxan-induced diabetic nephropathy. Inflammation. 2016;39(5):1783–97.PubMedCrossRef

13.

Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats. Toxicol Appl Pharmacol. 2020;15:401.

14.

Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology. 1994;45(6 Pt 2):579–84.PubMedCrossRef

15.

Söylemez H, Kiliç S, Atar M, Penbegül N, Sancaktutar AA, Bozkurt Y. Effects of micronised purified flavonoid fraction on pain, semen analysis and scrotal color Doppler parameters in patients with painful varicocele; results of a randomized placebo-controlled study. Int Urol Nephrol. 2012;44(2):401–8.PubMedCrossRef

16.

Shalkami AS, Hassan MIA, Bakr AG. Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis. Hum Exp Toxicol. 2018;37(1):78–86.PubMedCrossRef

17.

Arab HH, Salama SA, Omar HA, Arafa ESA, Maghrabi IA. Diosmin protects against ethanol-induced gastric injury in rats: novel anti-ulcer actions. PLoS One. 2015;10(3):e0122417.CrossRef

18.

Srinivasan S, Pari L. Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats. Chem Biol Interact. 2012;195(1):43–51.PubMedCrossRef

19.

Hasan HF, Abdel-Rafei MK, Galal SM. Diosmin attenuates radiation-induced hepatic fibrosis by boosting PPAR-γ expression and hampering miR-17-5p-activated canonical Wnt-β-catenin signaling. Biochem Cell Biol. 2017;95(3):400–14.PubMedCrossRef

20.

Abdel-Daim MM, Khalifa HA, Abushouk AI, Dkhil MA, Al-Quraishy SA. Diosmin attenuates methotrexate-induced hepatic, renal, and cardiac injury: a biochemical and histopathological study in mice. Oxid Med Cell Longev. 2017;2017:3281670.PubMedPubMedCentralCrossRef

21.

Navrátilová Z and the EDET study group. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous edema. Phlebolymphology. 2010;17(3):137–43.

22.

Feldo M, Woźniak M, Wójciak-Kosior M, Sowa I, Kot-Waśik A, Aszyk J, et al. Influence of diosmin treatment on the level of oxidative stress markers in patients with chronic venous insufficiency. Oxid Med Cell Longev. 2018;2018:2561705.PubMedPubMedCentralCrossRef

23.

Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (daflon 500® mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91(1):32–40.PubMedCrossRef

24.

Patel K, Gadewar M, Tahilyani V, Patel DK. A review on pharmacological and analytical aspects of diosmetin: a concise report. Chin J Integr Med. 2013;19:792–800.PubMedCrossRef

25.

Serra H, Mendes T, Bronze M, Simplício A. Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. Bioorg Med Chem. 2008;16(7):4009–18.PubMedCrossRef

26.

Bhattacharyya S, Pal S, Mohamed R, Singh P, Chattopadhyay S, Pal China S, et al. A nutraceutical composition containing diosmin and hesperidin has osteogenic and anti-resorptive effects and expands the anabolic window of teriparatide. Biomed Pharmacother. 2019;1:118.

27.

Amato C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin-PubMed. Angiology. 1994;45(6 Pt 2):531–6.PubMed

28.

Zhu T, Du M, Su H, Yang L. Pharmacokinetics of diosmin tablets in healthy volunteers|Request PDF. Chin J New Drugs. 2014;23(14):1674–8.

29.

Silvestro L, Tarcomnicu I, Dulea C, Attili NRBN, Ciuca V, Peru D, et al. Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquid-chromatography-mass spectrometry and ion mobility mass spectrometry. Anal Bioanal Chem. 2013;405(25):8295–310.PubMedPubMedCentralCrossRef

30.

Cova D, De Angelis L, Giavarini F, Palladini G, Perego R. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers-PubMed. Int J Clin Pharmacol Ther Toxicol. 1992;30(1):29–33.PubMed

31.

Barreca D, Laganà G, Bruno G, Magazù S, Bellocco E. Diosmin binding to human serum albumin and its preventive action against degradation due to oxidative injuries. Biochimie. 2013;95(11):2042–9.PubMedCrossRef

32.

Poór M, Boda G, Mohos V, Kuzma M, Bálint M, Hetényi C, et al. Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin. Biomed Pharmacother. 2018;1(102):912–21.CrossRef

33.

Mrkalić E, Jelić R, Stojanović S, Sovrlić M. Interaction between olanzapine and human serum albumin and effect of metal ions, caffeine and flavonoids on the binding: a spectroscopic study. Spectrochim Acta A Mol Biomol Spectrosc. 2021;15:249.

34.

Chen X, Xu L, Guo S, Wang Z, Jiang L, Wang F, et al. Profiling and comparison of the metabolites of diosmetin and diosmin in rat urine, plasma and feces using UHPLC-LTQ-Orbitrap MS n. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;15(1124):58–71.

35.

Androutsopoulos V, Wilsher N, Arroo R, Potter G. Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett. 2009;274(1):54–60.PubMedCrossRef

36.

Wang L, Chen Q, Zhu L, Li Q, Zeng X, Lu L, et al. Metabolic disposition of luteolin is mediated by the interplay of UDP-glucuronosyltransferases and catechol-O-methyltransferases in rats. Drug Metab Dispos. 2017;45(3):306–15.PubMedPubMedCentralCrossRef

37.

Wang S, Li X, Niu Y, Liu Y, Zhu Y, Lu X, et al. Identification and screening of chemical constituents with hepatoprotective effects from three traditional Chinese medicines for treating jaundice. J Sep Sci. 2016;39(19):3690–9.PubMedCrossRef

38.

Zeng X, Shi J, Zhao M, Chen Q, Wang L, Jiang H, et al. Regioselective glucuronidation of diosmetin and chrysoeriol by the interplay of glucuronidation and transport in UGT1A9-Overexpressing hela cells. PLoS One. 2016;11(11):e0166239.PubMedPubMedCentralCrossRef

39.

Imam F, Al-Harbi NO, Al-Harbi MM, Ansari MA, Zoheir KMA, Iqbal M, et al. Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-κB activation against LPS-induced acute lung injury in mice. Pharmacol Res. 2015;1(102):1–11.CrossRef

40.

Hsu CC, Lin MH, Cheng JT, Wu MC. Antihyperglycaemic action of diosmin, a citrus flavonoid, is induced through endogenous β-endorphin in type I-like diabetic rats. Clin Exp Pharmacol Physiol. 2017;44(5):549–55.PubMedCrossRef

41.

Firdous SM, Hazra S, Gopinath SCB, El-Desouky GE, Aboul-Soud MAM. Antihyperlipidemic potential of diosmin in Swiss Albino mice with high-fat diet induced hyperlipidemia. Saudi J Biol Sci. 2021;28(1):109–15.PubMedCrossRef

42.

Perumal S, Langeshwaran K, Selvaraj J, Ponnulakshmi R, Shyamaladevi B, Balasubramanian MP. Effect of diosmin on apoptotic signaling molecules in N-nitrosodiethylamine-induced hepatocellular carcinoma in experimental rats. Mol Cell Biochem. 2018;449(1–2):27–37.PubMedCrossRef

43.

Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4(4):CD003229.PubMed

44.

Juteau N, Bakri F, Pomies J, Foulon C, Rigaudy P, Pillion G, et al. The human saphenous vein in pharmacology: effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction-PubMed. Int Angiol. 1995;14(3 Suppl 1):8–13.PubMed

45.

Struckmann J, Nicolaides A. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology. 1994;45(6):495–504.CrossRef

46.

Damon M, Flandre O, Michel F, Perdrix L, Labrid C, Crastes de Paulet A. Effect of chronic treatment with a purified flavonoid fraction on inflammatory granuloma in the rat. Study of prostaglandin E2 and F2 alpha and thromboxane B2 release and histological changes-PubMed. Arzneimittelforschung. 1987;37(10):1149–53.PubMed

47.

Labrid C. Pharmacologic properties of Daflon 500 mg—PubMed. Angiology. 1994;45(6 Pt 2):524–30.PubMed

48.

Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology. 1997;48(1):77–85.PubMedCrossRef

49.

Senthamizhselvan O, Manivannan J, Silambarasan T, Raja B. Diosmin pretreatment improves cardiac function and suppresses oxidative stress in rat heart after ischemia/reperfusion. Eur J Pharmacol. 2014;5(736):131–7.CrossRef

50.

El-Fawal R, El Fayoumi H, Mahmoud H. Effects of diosmin and crocin on metabolic syndrome-associated cardio-vascular complications in rats. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(12):1523–36.PubMedCrossRef

51.

Queenthy S, Prince P, John B. Diosmin prevents isoproterenol-induced heart mitochondrial oxidative stress in rats. Cardiovasc Toxicol. 2018;18(2):120–30.CrossRef

52.

Queenthy S, Prince P, John B. Diosmin prevents left ventricular hypertrophy, adenosine triphosphatases dysfunction and electrolyte imbalance in experimentally induced myocardial infarcted rats. Eur J Pharmacol. 2017;5(814):124–9.

53.

de Almeida GKM, de Jesus ICG, Mesquita T, Miguel-dos-Santos R, dos Santos PH, de Moraes ER, et al. Post-ischemic reperfusion with diosmin attenuates myocardial injury through a nitric oxidase synthase-dependent mechanism. Life Sci. 2020;258:118188.PubMedCrossRef

54.

Friesenecker B, Tsai AG, Allegra C, Intaglietta M. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: In vivo observations in the hamster skin fold. Int J Microcirc Exp. 1994;14(1–2):50–5.CrossRef

55.

Sirlak M, Akar A, Eryilmaz S, Cetinkanat E, Ozcinar E, Kaya B, et al. Micronized purified flavonoid fraction in pretreating CABG patients—PubMed. Texas Hear Inst J. 2010;37(2):172–7.

56.

Struckmann J. Pharmacological and pharmacoclinical properties of Dalfon 500 mg®. Drugs of Today. 1995;31(SUPPL. E):29–36.

57.

Dholakiya SL, Benzeroual KE. Protective effect of diosmin on LPS-induced apoptosis in PC12 cells and inhibition of TNF-α expression. Toxicol Vitr. 2011;25(5):1039–44.CrossRef

58.

Berköz M. Diosmin suppresses the proinflammatory mediators in lipopolysaccharide-induced RAW264.7 macrophages via NF-κB and MAPKs signal pathways. Gen Physiol Biophys. 2019;38(4):315–24.PubMedCrossRef

59.

Zaragozá C, Villaescusa L, Monserrat J, Zaragozá F, Álvarez-Mon M. Potential therapeutic anti-inflammatory and immunomodulatory effects of dihydroflavones, flavones, and flavonols. Molecules. 2020;25(4):1017.PubMedCentralCrossRef

60.

Zheng Y, Zhang R, Shi W, Li L, Liu H, Chen Z, et al. Metabolism and pharmacological activities of the natural health-benefiting compound diosmin. Food Funct. 2020;11(10):8472–92.PubMedCrossRef

61.

Crespo ME, Gálvez J, Cruz T, Ocete MA, Zarzuelo A. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med. 1999;65(7):651–3.PubMedCrossRef

62.

Devaki T, Binuclara J, Raghunandakumar S, Asokkumar S, Naveenkumar C, Premkumar T. Anti-fibrotic effect of diosmin against DMN-induced liver fibrosis in rats: a biochemical analysis. Int J Res Pharm Nano Sci. 2013;2(3):283–92.

63.

Queenthy S, John B. Diosmin exhibits anti-hyperlipidemic effects in isoproterenol induced myocardial infarcted rats. Eur J Pharmacol. 2013;718(1–3):213–8.PubMedCrossRef

64.

Mirzaee S, Mansouri E, Shirani M, Zeinvand-Lorestani M, Khodayar MJ. Diosmin ameliorative effects on oxidative stress and fibrosis in paraquat-induced lung injury in mice. Environ Sci Pollut Res. 2019;26(36):36468–77.CrossRef

65.

Eraslan G, Sarıca ZS, Bayram LÇ, Tekeli MY, Kanbur M, Karabacak M. The effects of diosmin on aflatoxin-induced liver and kidney damage. Environ Sci Pollut Res. 2017;24:27931–41.CrossRef

66.

EL-Dakhly SM, Salama AAA, Hassanin SOM, Yassen NN, Hamza AA, Amin A. Aescin and diosmin each alone or in low dose-combination ameliorate liver damage induced by carbon tetrachloride in rats. BMC Res Notes. 2020;13:259.PubMedPubMedCentralCrossRef

67.

Elhelaly AE, AlBasher G, Alfarraj S, Almeer R, Bahbah EI, Fouda MMA, et al. Protective effects of hesperidin and diosmin against acrylamide-induced liver, kidney, and brain oxidative damage in rats. Environ Sci Pollut Res. 2019;26(34):35151–62.CrossRef

68.

Lamidi IY, Mikail HG, Adamu S, Akefe IO, Tijjani MB, Salihu SI, et al. Flavonoid fractions of diosmin and hesperidin mitigate lead acetate-induced biochemical, oxidative stress, and histopathological alterations in Wistar rats. Toxicol Res. 2021;1:1–12.

69.

Ali N, AlAsmari AF, Imam F, Ahmed MZ, Alqahtani F, Alharbi M, et al. Protective effect of diosmin against doxorubicin-induced nephrotoxicity. Saudi J Biol Sci. 2021;28(8):4375–83.PubMedPubMedCentralCrossRef

70.

Peruru R, Dodoala S. Therapeutic potential of diosmin, a citrus flavonoid against arsenic-induced neurotoxicity via suppression of NOX 4 and its subunits. Indian J Pharmacol. 2021;53(2):132.PubMedPubMedCentralCrossRef

71.

Tekeli MY, Eraslan G, Çakır Bayram L, Soyer SZ. Effect of diosmin on lipid peoxidation and organ damage against subacute deltamethrin exposure in rats. Environ Sci Pollut Res. 2020;28(13):15890–908.CrossRef

72.

Abogresha NM, Mohammed SS, Hosny MM, Abdallah HY, Gadallah AM, Greish SM. Diosmin mitigates cyclophosphamide induced premature ovarian insufficiency in rat model. Int J Mol Sci. 2021;22(6):3044.PubMedPubMedCentralCrossRef

73.

Germoush MO. Diosmin protects against cyclophosphamide-induced liver injury through attenuation of oxidative stress, inflammation and apoptosis. Int J Pharmacol. 2016;12(6):644–54.CrossRef

74.

Manuel y Keenoy B, Vertommen J, De Leeuw I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients—PubMed. Diabetes Nutr Metab. 1999;12(4):256–63.PubMed

75.

Pari L, Srinivasan S. Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Biomed Pharmacother. 2010;64(7):477–81.PubMedCrossRef

76.

Pari L, Srinivasan S, Saddiq M. Preventive effect of diosmin, a bioflavonoid, on glycoprotein changes in streptozotocin-nicotinamide-induced type 2 diabetic rats. Int J Pharm Sci Res. 2010;1(10):89–95.

77.

Srinivasan S, Pari L. Antihyperlipidemic effect of diosmin: a citrus flavonoid on lipid metabolism in experimental diabetic rats. J Funct Foods. 2013;5(1):484–92.CrossRef

78.

Kampmann U, Christensen B, Nielsen TS, Pedersen SB, Ørskov L, Lund S, et al. GLUT4 and UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PLoS One. 2011;6(11):e27854.PubMedPubMedCentralCrossRef

79.

Ali FEM, Bakr AG, Abo-youssef AM, Azouz AA, Hemeida RAM. Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. Life Sci. 2018;15(207):50–60.CrossRef

80.

Ali FEM, Azouz AA, Bakr AG, Abo-youssef AM, Hemeida RAM. Hepatoprotective effects of diosmin and/or sildenafil against cholestatic liver cirrhosis: the role of Keap-1/Nrf-2 and P38-MAPK/NF-κB/iNOS signaling pathway. Food Chem Toxicol. 2018;1(120):294–304.CrossRef

81.

Lewinska A, Adamczyk-Grochala J, Kwasniewicz E, Deregowska A, Wnuk M. Diosmin-induced senescence, apoptosis and autophagy in breast cancer cells of different p53 status and ERK activity. Toxicol Lett. 2017;4(265):117–30.CrossRef

82.

Lewinska A, Siwak J, Rzeszutek I, Wnuk M. Diosmin induces genotoxicity and apoptosis in DU145 prostate cancer cell line. Toxicol Vitr. 2015;29(3):417–25.CrossRef

83.

Dung TD, Lin CH, Binh TV, Hsu HH, Su CC, Lin YM, et al. Diosmin induces cell apoptosis through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells and blocks tumour growth in xenografted nude mice. Food Chem. 2012;132(4):2065–73.CrossRef

84.

Álvarez N, Vicente V, Martínez C. Synergistic effect of diosmin and interferon-α on metastatic pulmonary melanoma. Cancer Biother Radiopharm. 2009;24(3):347–52.PubMed

85.

Zhao Y, Zhang J, Liu W. Diosmin regulates oxidative stress and inflammatory marker levels in N-Methyl-N-nitrosourea-induced gastric carcinogenesis in rats. J Environ Pathol Toxicol Oncol. 2020;39(4):375–84.PubMedCrossRef

86.

Bertozzi MM, Rossaneis AC, Fattori V, Longhi-Balbinot DT, Freitas A, Cunha FQ, et al. Diosmin reduces chronic constriction injury-induced neuropathic pain in mice. Chem Biol Interact. 2017;1(273):180–9.CrossRef

87.

Carballo-Villalobos AI, González-Trujano ME, Pellicer F, Alvarado-Vásquez N, López-Muñoz FJ. Central and peripheral anti-hyperalgesic effects of diosmin in a neuropathic pain model in rats. Biomed Pharmacother. 2018;1(97):310–20.CrossRef

88.

Carballo-Villalobos AI, González-Trujano ME, Pellicer F, López-Muñoz FJ. Antihyperalgesic effect of hesperidin improves with diosmin in experimental neuropathic pain. Biomed Res Int. 2016;2016:8263463.PubMedPubMedCentralCrossRef

89.

Adamante G, de Almeida AS, Rigo FK, da Silva SE, Coelho YO, De Prá SDT, et al. Diosmetin as a novel transient receptor potential vanilloid 1 antagonist with antinociceptive activity in mice. Life Sci. 2019;1(216):215–26.CrossRef

90.

Sarhan HKA, Saleh AMA, Hammam OAE, Atta AH, El-Nehrery IM. The protective role of Diosmin, Hesperidine combination against heavy metals toxicity in Wistar albino rats: BIOCHEMICAL, IMMUNOHISTOCHEMICAL AND MOLECULAR STUDIEs. Egypt J Chem. 2021;64(8):4531–43.CrossRef

91.

Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem Pharmacol. 2008;75(6):1426–37.PubMedCrossRef

92.

Quintieri L, Bortolozzo S, Stragliotto S, Moro S, Pavanetto M, Nassi A, et al. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug Metab Pharmacokinet. 2010;25(5):466–76.PubMedCrossRef

93.

Quintieri L, Palatini P, Moro S, Floreani M. Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin. Drug Metab Pharmacokinet. 2011;26(6):559–68.PubMedCrossRef

94.

Chen JJ, Zhang JX, Zhang XQ, Qi MJ, Shi MZ, Yang J, et al. Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro. Toxicol Appl Pharmacol. 2017;1(334):1–7.CrossRef

95.

Bedada SK, Neerati P. Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(2):115–21.PubMedCrossRef

96.

Rajnarayana K, Reddy MS, Krishna DR. Diosmin pretreatment affects bioavailability of metronidazole. Eur J Clin Pharmacol. 2003;58(12):803–7.PubMedCrossRef

97.

Rajnarayana K, Venkatesham A, Krishna DR. Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers. Drug Metabol Drug Interact. 2007;22(2–3):165–74.PubMed

98.

Rajnarayana K, Venkatesham A, Nagulu M, Srinivas M, Krishna DR. Influence of diosmin pretreatment on the pharmacokinetics of chlorzoxazone in healthy male volunteers. Drug Metabol Drug Interact. 2008;23(3–4):311–22.PubMed

99.

Bedada S, Boga P. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879–84.PubMedCrossRef

100.

Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1–16.PubMedCrossRef

101.

Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005;45:477–94.PubMedCrossRef

102.

Yacobi A, Zlotnick S, Colaizzi J, Moros D, Masson E, Abolfathi Z, et al. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine. Clin Pharmacol Ther. 1999;65(4):389–94.PubMedCrossRef

103.

Hye HY, Lee M, Hye JC, Sang KL, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal caco-2 cells. J Agric Food Chem. 2007;55(18):7620–5.CrossRef

104.

Neerati P, Bedada S. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. Pharmacol Rep. 2015;67(2):339–44.PubMedCrossRef

105.

Bedada SK, Boga PK, Kotakonda HK. The effect of diosmin on the pharmacokinetics of fexofenadine in healthy human volunteers. Xenobiotica. 2017;47(3):230–5.PubMedCrossRef

106.

Gopalakrishnan V, Iyyam Pillai S, Subramanian SP. Synthesis, spectral characterization, and biochemical evaluation of antidiabetic properties of a new zinc-diosmin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in rats. Biochem Res Int. 2015;2015:350829.PubMedPubMedCentralCrossRef

107.

Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J basic Clin Pharm. 2016;7(2):27.PubMedPubMedCentralCrossRef

108.

Anwer MK, Shakeel F. Measurement and correlation of solubility of diosmin in four pure solvents and β-cyclodextrin solution at 298.15 K to 333.15 K. Chin J Chem Eng. 2015;23(5):812–5.CrossRef

109.

Piponski M, Stoimenova TB, Topkoska M, Stefov S, Piponska M, Serafimovska GT. Development and validation of a fast and simple RP-HPLC method for the determination of diosmin and hesperidin. Maced J Chem Chem Eng. 2018;37(2):127–34.CrossRef

Titel: Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review
verfasst von: Samar H. Gerges
Sara A. Wahdan
Doaa A. Elsherbiny
Ebtehal El-Demerdash
Publikationsdatum: 01.01.2022
Verlag: Springer International Publishing
Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics / Ausgabe 1/2022
Print ISSN: 0378-7966
Elektronische ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-021-00731-y

Springer Medizin

Abstract

Graphic Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats

A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects

Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

Andrographis paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability